United States-based Merck's HIV Therapy Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) has achieved primary efficacy endpoint in phase three Drive-Shift study that is evaluating to convert to Delstrigo from other antiretroviral treatment regimens, it was reported on Friday.

The company has released the first presentation of data from the Phase 3 DRIVE-SHIFT trial assessing a switch of medication to Delstrigo, a once-daily fixed-dose combination tablet of doravirine (100mg), lamivudine (3TC, 300mg) and tenofovir disoproxil fumarate (TDF, 300mg), in adults with HIV-1 infection who showcased virological suppression for around six months on a stable antiretroviral treatment regimen.

The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels